ALTAVILLA, AMELIA
ALTAVILLA, AMELIA
Dottorandi
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma
2020 Lolli C.; Altavilla A.; Conteduca V.; Farolfi A.; Casadei C.; Schepisi G.; Banna G.L.; De Giorgi U.
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials
2013 Iacovelli R.; Altavilla A.; Procopio G.; Bracarda S.; Santoni M.; Cascinu S.; Cortesi E.
Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: A personal view
2014 Bracarda S.; Sisani M.; Marrocolo F.; Hamzaj A.; Del Buono S.; Altavilla A.
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome
2021 Conteduca V.; Scarpi E.; Caroli P.; Lolli C.; Gurioli G.; Brighi N.; Poti G.; Farolfi A.; Altavilla A.; Schepisi G.; Matteucci F.; Paganelli G.; De Giorgi U.
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)]
2016 Bracarda S.; Iacovelli R.; Boni L.; Rizzo M.; Derosa L.; Rossi M.; Galli L.; Procopio G.; Sisani M.; Longo F.; Santoni M.; Morelli F.; G. Di Lorenzo; Altavilla A.; Porta C.; Camerini A.; Escudier B.
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation
2015 Bracarda S.; Caserta C.; Galli L.; Carlini P.; Pastina I.; Sisani M.; Scali S.; Hamzaj A.; Derosa L.; Felici A.; Rossi M.; Altavilla A.; Chioni A.; De Angelis V.
Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma
2013 Panebianco V.; Iacovelli R.; Barchetti F.; Altavilla A.; Forte V.; Sciarra A.; Cortesi E.; Catalano C.
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches
2019 Farolfi A.; Gurioli G.; Fugazzola P.; Burgio S.L.; Casanova C.; Ravaglia G.; Altavilla A.; Costantini M.; Amadori A.; Framarini M.; Ansaloni L.; De Giorgi U.
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies
2015 Bracarda S.; Altavilla A.; Hamzaj A.; Sisani M.; Marrocolo F.; Del Buono S.; Danielli R.
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy
2021 Schepisi G.; Casadei C.; Toma I.; Poti G.; Iaia M.L.; Farolfi A.; Conteduca V.; Lolli C.; Ravaglia G.; Brighi N.; Altavilla A.; Martinelli G.; De Giorgi U.
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study
2024 Casadei C.; Scarpi E.; Conteduca V.; Gurioli G.; Cursano M.C.; Brighi N.; Lolli C.; Schepisi G.; Basso U.; Fornarini G.; Bleve S.; Farolfi A.; Altavilla A.; Burgio S.L.; Giunta E.F.; Gianni C.; Filograna A.; Ulivi P.; Olmos D.; Castro E.; De Giorgi U.
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant
2012 Altavilla, A.; Iacovelli, R.; Procopio, G.; Alesini, D.; Risi, E.; Campenn{\`i}, G.M.; Palazzo, A.; Cortesi, E.
Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules
2012 Alesini D.; Iacovelli R.; Palazzo A.; Altavilla A.; Risi E.; Urbano F.; Manai C.; Passaro A.; Magri V.; Cortesi E.
Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert
2012 Altavilla A.; Iacovelli R.; Procopio G.; Cortesi E.
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide
2019 Lolli C.; De Lisi D.; Conteduca V.; Gurioli G.; Scarpi E.; Schepisi G.; Ravaglia G.; Menna C.; Farolfi A.; Altavilla A.; Burgio S.L.; Tonini G.; Santini D.; De Giorgi U.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma | Lolli C.; Altavilla A.; Conteduca V.; Farolfi A.; Casadei C.; Schepisi G.; Banna G.L.; De Giorgi U. | 2020-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2 A meta-analysis of published trials | Iacovelli R.; Altavilla A.; Procopio G.; Bracarda S.; Santoni M.; Cascinu S.; Cortesi E. | 2013-01-01 | PROSTATE CANCER AND PROSTATIC DISEASES | - | 1.01 Articolo in rivista | - |
| Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: A personal view | Bracarda S.; Sisani M.; Marrocolo F.; Hamzaj A.; Del Buono S.; Altavilla A. | 2014-01-01 | EXPERT REVIEW OF ANTICANCER THERAPY | - | 1.01 Articolo in rivista | - |
| Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome | Conteduca V.; Scarpi E.; Caroli P.; Lolli C.; Gurioli G.; Brighi N.; Poti G.; Farolfi A.; Altavil...la A.; Schepisi G.; Matteucci F.; Paganelli G.; De Giorgi U. | 2021-01-01 | MOLECULAR ONCOLOGY | - | 1.01 Articolo in rivista | Molecular Oncology - 2021 - Conteduca - Combining liquid biopsy and functional imaging analysis in metastatic.pdf; Supplementary materials.zip |
| Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)] | Bracarda S.; Iacovelli R.; Boni L.; Rizzo M.; Derosa L.; Rossi M.; Galli L.; Procopio G.; Sisani ...M.; Longo F.; Santoni M.; Morelli F.; G. Di Lorenzo; Altavilla A.; Porta C.; Camerini A.; Escudier B. | 2016-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Docetaxel rechallenge in metastatic castration-resistant prostate cancer: Any place in the modern treatment scenario? An intention to treat evaluation | Bracarda S.; Caserta C.; Galli L.; Carlini P.; Pastina I.; Sisani M.; Scali S.; Hamzaj A.; Derosa... L.; Felici A.; Rossi M.; Altavilla A.; Chioni A.; De Angelis V. | 2015-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Dynamic contrast-enhanced magnetic resonance imaging in the early evaluation of anti-angiogenic therapy in metastatic renal cell carcinoma | Panebianco V.; Iacovelli R.; Barchetti F.; Altavilla A.; Forte V.; Sciarra A.; Cortesi E.; Catala...no C. | 2013-01-01 | ANTICANCER RESEARCH | - | 1.01 Articolo in rivista | - |
| Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches | Farolfi A.; Gurioli G.; Fugazzola P.; Burgio S.L.; Casanova C.; Ravaglia G.; Altavilla A.; Costan...tini M.; Amadori A.; Framarini M.; Ansaloni L.; De Giorgi U. | 2019-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | - |
| Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies | Bracarda S.; Altavilla A.; Hamzaj A.; Sisani M.; Marrocolo F.; Del Buono S.; Danielli R. | 2015-01-01 | SEMINARS IN ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy | Schepisi G.; Casadei C.; Toma I.; Poti G.; Iaia M.L.; Farolfi A.; Conteduca V.; Lolli C.; Ravagli...a G.; Brighi N.; Altavilla A.; Martinelli G.; De Giorgi U. | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-13-00840-v2.pdf |
| Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study | Casadei C.; Scarpi E.; Conteduca V.; Gurioli G.; Cursano M.C.; Brighi N.; Lolli C.; Schepisi G.; ...Basso U.; Fornarini G.; Bleve S.; Farolfi A.; Altavilla A.; Burgio S.L.; Giunta E.F.; Gianni C.; Filograna A.; Ulivi P.; Olmos D.; Castro E.; De Giorgi U. | 2024-01-01 | EUROPEAN UROLOGY OPEN SCIENCE | - | 1.01 Articolo in rivista | - |
| Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant | Altavilla, A.; Iacovelli, R.; Procopio, G.; Alesini, D.; Risi, E.; Campenn{\`i}, G.M.; Palazzo, A....; Cortesi, E. | 2012-01-01 | Cancer Biology & Therapy | - | 1.01 Articolo in rivista | - |
| Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules | Alesini D.; Iacovelli R.; Palazzo A.; Altavilla A.; Risi E.; Urbano F.; Manai C.; Passaro A.; Mag...ri V.; Cortesi E. | 2012-01-01 | ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Post-docetaxel therapy in castration resistant prostate cancer – the forest is growing in the desert | Altavilla A.; Iacovelli R.; Procopio G.; Cortesi E. | 2012-01-01 | THERAPEUTIC ADVANCES IN UROLOGY | - | 1.01 Articolo in rivista | - |
| Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide | Lolli C.; De Lisi D.; Conteduca V.; Gurioli G.; Scarpi E.; Schepisi G.; Ravaglia G.; Menna C.; Fa...rolfi A.; Altavilla A.; Burgio S.L.; Tonini G.; Santini D.; De Giorgi U. | 2019-01-01 | THE PROSTATE | - | 1.01 Articolo in rivista | - |